Thus, future studies should capitalize on this opportunity to incorporate patient-derived xenograft models when testing the efficacy of TRAIL-therapies in disrupting the OPG/TRAIL interaction in tumor microenvironments that closely resemble human breast cancer. Here, TNFSF10 is linked to breast carcinoma.